CHARM Therapeutics

A few weeks ago, we gathered together for the CHARM Therapeutics summer event. This was made even more special as we marked the opening of our new lab at the Babraham Research Campus. The atmosphere was electric, filled with the excitement of our growth and the anticipation of a bright future ahead! 🚀 🚀 🚀 #biotechnology #drugdiscovery #deeplearning

We’re delighted to have been included in Newcomer’s article discussing the new frontier of AI-driven drug discovery in biotech, which highlights how biotech startup investors are excited about our capabilities to single out proteins for the treatment of previously untreatable diseases.     To read: https://lnkd.in/eHHrCv9f     #ai #drugdiscovery #biotechnology #article 

Last Friday, our CEO Laksh Aithani gave the keynote talk at the ‘Machine Learning for Life and Material Science: From Theory to Industry applications’ session at [ICML] Int'l Conference on Machine Learning in Vienna, where he showcased the ways in which AI-driven platforms such as our protein-ligand prediction platform DragonFold are transforming the life science industry.    #ai #drugdiscovery #biotechnoliogy #machinelearning #ICML24

We hosted our annual summer party at Chilston Park Hotel in Maidstone, bringing together all of our teams based in London, Cambridge, and remotely. Together, we enjoyed a fun afternoon of good food and great company, and even had a go at duck herding!   #social #summerparty #team

We are excited to announce that CHARM Therapeutics has been featured as the highest rated drug discovery company in Sifted’s latest roundup of drug discovery companies to watch. The companies were selected based on a range of criteria across the following categories: funding history, investor prominence, growth, traction, and founder strength. CHARM Therapeutics stands out among these top AI companies in part due to DragonFold, our advanced protein-ligand intelligence platform which uses deep learning AI technology to design, test and optimize new molecules for previously undruggable targets with unprecedented precision to develop impactful medicines, but also reflects the strength of our high energy, talented team. Find the full list of Sifted’s start-ups to watch here: https://lnkd.in/eimQzZ8X #deeplearning #AI

Discover how our upgraded computing infrastructure is enhancing our ability to design new therapeutics. By leveraging powerful GPU technology and advanced AI, we're making significant strides in healthcare innovation.

🚀 Exciting News at CHARM Therapeutics! 🚀 We are thrilled to give a shoutout to one of our new synthetic chemistry recruits Elliot Bailey, for his first-author publication that was published today in Nature Comms. and we couldn't be prouder. 🐲 Check out the groundbreaking research here: https://lnkd.in/eq2QCfR4 Join us in congratulating Elliot on this fantastic accomplishment and welcoming him to the CHARM Therapeutics family. We can't wait to see the amazing contributions he'll bring to our team! 💡👨🔬 👏

Yesterday, our Chief Scientific Officer Sarah Skerratt, FRSC spoke at the Pharmaron Chemistry for Life Science Symposium about the drug discovery capabilities of our platform DragonFold.

Yesterday, our Chief Scientific Officer Dr Sarah Skerratt, spoke at the #GenAI4Pharma London. She shared how our #DragonFold platform is turning advanced protein-ligand prediction into innovative new therapies for hard-to-treat diseases. We’d like to thank Amazon Web Services (AWS), Health Disruptors Inc., and Slalom for co-hosting this event. #deeplearning #AI

A recent note from analysts at the investment bank Stifel helps shed light on how to view the AI and machine learning space now and what to watch for the future. The key takeout: generative AI will be most impactful for those willing to be radical and seek to use the technology to take the medical field beyond incremental change. We’re pleased to say that CHARM is named as one of those companies.    The author of the report, analyst Tim Opler questions the value of AI in some elements of drug discovery and points out that we have yet to see a blockbuster drug based on AI approved. Clinical delivery will be critical to dispelling scepticism. But he points to examples of growing evidence that generative AI can support the drug discovery and development process, and of significant improvements which are starting to embed themselves in our industry.     CHARM is mentioned, alongside peers such as Eikon, Insitro, and Isomorphic Labs as “taking fresh approaches to tough problems”. Essentially, Tim’s conclusion is that the real power of ML is not to simply make the existing way of doing things faster, but to find entirely new ways of looking at problems.     #ai #deeplearning